CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

The Clinical Potential of Interleukin Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Outline the role of the IL-23/Th17 and Th1 pathways in the pathogenesis of PsO and PsA and its implications for treatment
Evaluate key efficacy and safety data for approved IL inhibitors for the treatment of PsO and PsA
Describe the clinical rationale and considerations for IL inhibitors for the treatment of PsO and PsA
Integrate IL inhibitors into collaborative treatment strategies for patients with PsO and PsA, where appropriate

Please rate the faculty on the following:

Joseph Merola, MD: Knowledge, expertise, and teaching ability

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.

How many patients with Psoriasis and Psoriatic Arthritis do you see during a typical week? 

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
Which of the following cytokines promotes immune cell differentiation, induction of a Th17 immune response, and the production of inflammatory cytokines involved in psoriasis and psoriatic arthritis pathogenesis?
In the Phase 2b FRONTIER 1 clinical trial , a greater proportion of patients with moderate to severe psoriasis who received which of the following achieved PASI 75 (primary endpoint) as well as PASI 90 and PASI 100 compared to placebo at week 16?
Which of the following demonstrated significant and durable improvements in symptoms of psoriatic arthritis in patients with PsA who were intolerant to prior TNF-a therapy?
How confident are you in your ability to appropriately utilize IL inhibitors in management strategies for psoriasis and psoriatic arthritis?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often: (select all that apply)